S U B M I S S I O N  T I M E L I N E

• Research on all diseases is considered. Study methods include, but are not limited to, conjoint analysis, large database analysis, quasi-experimental analysis, literature or record review, modeling, naturalistic (observational) studies, randomized clinical trials and surveys.
• Research on all health care interventions is considered including drugs, behavioral modification, disease prevention, gene therapy, medical device, screening, diagnostic procedures, dietary, health education, radiation therapy, and surgical procedures.
• Reviews or methods papers are also considered as research abstracts.
• Research abstracts must be organized as follows: OBJECTIVES: METHODS: RESULTS: CONCLUSIONS:
• ALL ABSTRACTS MUST BE SUBMITTED THROUGH ISPOR’S ONLINE ABSTRACT SYSTEM VIA WWW.ISPOR.ORG. If you do not have internet access, please fax or phone your request for abstract submission instructions to ISPOR at TEL 1-609-219-0773 ext.20 or FAX 1-609-219-0774.
• All abstract submissions and presentations must be in English.
• Annual Meeting registration is required for all presenters.
• Expenses associated with the submission and presentation of an abstract are the responsibility of the presenter.
• The presenters of research are required to disclose financial support. Abstract review will NOT be based on this information.
• Any human experimentation must conform with the principles of the Declaration of Helsinki of the World Medical Association (Clin Res.1992; 40: 653-660).
• Accepted abstracts will be published AS SUBMITTED in Value in Health and distributed at the Annual Meeting. Changes to abstracts will not be accepted after the Submission Deadline therefore, they should be carefully written and edited prior to submission.\
• Research that has been published or presented at any national or international meeting prior to this Meeting is discouraged.
• The abstract, excluding title and author information, should be no longer than 300 words.
• The use of tables and graphs in your abstract submission is not allowed.
• Research RESULTS must be included for an abstract to be considered for presentation.

ALL ABSTRACTS MUST BE submitted By January 12, 2004

TOPICS FOR RESEARCH SUBMISSIONS:
Research submissions on the following topics are considered:

• Clinical Outcomes Studies
• Cost Studies
• Quality of Life/Utility/Preference Studies
• Health Policy
• Methodology Issues.

Topic subcategories are listed below to aid in your selection.

DISEASE/DISORDER FOR RESEARCH SUBMISSIONS:
When submitting your abstract, you must select the DISEASE/ DISORDER that best describes your research. If no disease or multiple diseases apply to your abstract, select Multiple Diseases/No Specific Disease. If the disease area is not listed, select Other.

CRITERIA FOR EVALUATION OF RESEARCH ABSTRACTS:
Research abstracts will be evaluated on the following criteria. Note: For studies involving data collection or analysis, the abstract will be REJECTED if RESULTS are NOT included.

Quality of the Study Criteria for research study abstracts:
1. Research design is appropriate and transparent.
2. Data sources are appropriate and transparent.
3. Data analyses are appropriate and transparent.
4. Results ARE INCLUDED and are transparent and comprehensible.
5. Conclusions are consistent with the results.

Methods and concepts abstract criteria:
1. Approach to method and/or concept is apparent.
2. Aarepproach represents an advancement or is innovative.
3. Practical implications/recommendations provided.
4. Papers do NOT need to be organized:
Objectives: Methods: Results: Conclusions:

Quality of the Abstract Presentation Criteria:
1. Objectives/research questions are clearly stated and objectives are addressed.
2. Factual information is kept separate from interpretations or implications / unbiased presentation.
3. Implications/results, as presented, are easy to understand.

TOPICS FOR WORKSHOP SUBMISSIONS:
Workshop submissions are designed to share novel and innovative experiences in either the conduct of pharmacoeconomics and outcomes research studies or the interpretation and use of pharmacoeconomics outcomes information in health care policy development. Workshop submissions are accepted on the following TOPICS:

• Clinical study methodology issues including pharmacoepidemiology
• Cost study methodology issues
• Quality of life study methodology issues including patient reported outcomes
• Preference-based studies methodology issues including utility studies
• Formulary development research issues
• Health care policy development issues using outcomes research
• Risk assessment/risk management issues
• Compliance issues

Criteria for Evaluation of Contributed Workshops:
• The workshop objective(s) are clearly stated.
• The objective(s) can be achieved in the 60 minutes allotted for this workshop.
• The information / issue(s) presented are novel or innovative.
• The information / issue(s) presented is valuable to the pharmacoeconomic &
outcomes researcher or the health care decision-maker.
• There is an audience interactive element in the workshop.
• The workshop does NOT appear to be advertising the presenter’s company’s
services or products.

ABSTRACT REVIEW PROCESS AND NOTIFICATION OF AUTHORS:

• All research abstracts will be peer reviewed by blinded reviewers. Research abstracts will be evaluated based on the items listed under Research Evaluation Criteria. Contributed Workshop Abstracts will be evaluated based
on relevance and completeness of information presented based on the Contributed Workshop Criteria given above.
• Authors will be notified no later than Monday, March 1, 2004 regarding abstract acceptance and placement in the Annual Meeting program.

PRESENTATION OF RESEARCH ABSTRACTS:

PODIUM PRESENTATIONS
• All oral presentations will be programmed into 15-minute time slots. You will have 12 minutes for presentation and 3 minutes for questions and discussion. It is important that you not exceed 15 minutes. Financial support for the research must be presented at the beginning of the presentation.
• Audio visual equipment: An LCD projector and laptop computer will be provided. Slide projection or overhead transparency projection are N O T allowed .
• YOU ARE REQUIRED TO BRING AT LEAST 100 HANDOUTS OF YOUR PRESENTATION MATERIAL.
• Presenter MUST email electronic slides in advance to the ISPOR office.

POSTER PRESENTATIONS
• Poster Session I is Monday , May 17 from 9:45am until 8:00pm.
• Poster Session II is Tuesday, May 18 from 10:15am until Wednesday, May 19 at 10:45pm.
• At least one author must be present at the designated times outlined in the acceptance letter.
• The abstract title and authors must be placed at the top of the board, and the lettering must be at least 1 inch high. A copy of the abstract, typed in large print, must be placed in the upper left hand corner of the board. Subtitles should correspond to those used in your abstract submission. Illustrations, charts, tables, lettering, and drawings must be readable from distances of at least three feet. Financial support must be displayed at the lower right hand corner of the board.
•Mounting materials will be available on-site.
• YOU ARE REQUIRED TO BRING AT LEAST 100 HANDOUTS OF YOUR PRESENTATION MATERIAL.

PRESENTATION OF CONTRIBUTED WORKSHOP ABSTRACTS:
• All workshops will be programmed into 60-minute time periods.
• Workshops may be presented by a single presenter or multiple presenters.
• A minimum of 15 minutes of structured audience participation is required.
• Visual equipment: an LCD projector and screen will be provided in each room. However, YOU MUST BRING YOUR OWN LAPTOP COMPUTER.

For Contributed Issue Panel proposal instructions please go to page:
http://www.ispor.org/meetings/va0504/panels_instr.asp
 

9th Annual International Meeting Main Page

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2008 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.